
lifespin GmbH is a pioneering technology company that merges NMR, metabolomics, and AI to create a metabolomic digital twin for precision medicine. Their platform digitizes human metabolomes using NMR technology and proprietary AI algorithms, enabling rapid, scalable, and affordable health assessments from blood samples. With a proprietary database of over 250,000 human metabolome profiles and the ability to detect more than 700 diseases, lifespin offers a cloud-based SaaS product for healthcare professionals to deliver personalized, proactive, and continuous healthcare insights. The company focuses on affordability and scalability to make precision medicine accessible globally, leveraging advanced metabolomic profiling and AI for early disease detection and health monitoring.

lifespin GmbH is a pioneering technology company that merges NMR, metabolomics, and AI to create a metabolomic digital twin for precision medicine. Their platform digitizes human metabolomes using NMR technology and proprietary AI algorithms, enabling rapid, scalable, and affordable health assessments from blood samples. With a proprietary database of over 250,000 human metabolome profiles and the ability to detect more than 700 diseases, lifespin offers a cloud-based SaaS product for healthcare professionals to deliver personalized, proactive, and continuous healthcare insights. The company focuses on affordability and scalability to make precision medicine accessible globally, leveraging advanced metabolomic profiling and AI for early disease detection and health monitoring.
Founded: Apr 6, 2017 (Regensburg, Bavaria, Germany)
Founders: Dr. Fritz Huber; Dr. Renate Kirchhöfer
Product: Digitizes human metabolomes using NMR and AI to enable rapid, scalable health assessments for early disease detection and monitoring
Funding: Seed / Early VC activity; latest disclosed round announced 2024-04-04 (investor: Artificial Intelligence Factory)
Metabolomics and health-data analytics for precision medicine and early disease detection
2017
Health data / Metabolomics / Precision medicine
Announced date available; amount not disclosed in accessible records.
Investors listed for an early-VC entry in Feb 2024; amount not shown in accessible view.
Entry dated Dec 2021 present with an amount shown as €0.0 in the accessible view (interpretation unclear).